Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details of the study appear in the November issue of ...
2009 NOV 16 ... According to recent research from Mie, Japan, "The efficacy of infliximab for endoscopic recurrence after resection of Crohn's disease (CD) has not yet been ...
2009 NOV 23 ... potential efficacy of a chimaeric antitumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc). A 26-week open-label ...
2009 NOV 16 ... female, and most (73, 70%) had rheumatoid arthritis. NTM infections were associated with infliximab (n = 73), etanercept (n = 25), and adalimumab (n = 7); most patients were taking ...
2009 NOV 16 ... possessing a well-established lipolytic effect. In Crohn's disease (CD) patients, infliximab therapy may thus result in visceral fat accumulation, which is associated with an ...
2009 NOV 9 ... data from the WELCOME trial, which studied patients who had been on the anti-TNF therapy infliximab, but failed or developed a hypersensitivity to the treatment, will be presented this ...
2009 NOV 23 ... of psoriasis in Canada and the United States: alefacept, efalizumab, etanercept, infliximab, adalimumab, and ustekinumab," researchers in Montreal, Canada report. ...
2009 NOV 23 ... reduction in Psoriasis Area and Severity Index score (PASI 75). Pooled NNTs were 1.3 (infliximab), 1.5 (ustekinumab 90 mg), 1.6 (adalimumab and ustekinumab 45 mg), 2.3 (etanercept), 4.1 ...
2009 NOV 9 ... According to a study from Budapest, Hungary, "Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, ...
2009 NOV 2 ... Scientists discuss in 'Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients' new ...
2009 NOV 9 ... According to recent research from the United States, "The efficacy of infliximab for treating patients with ulcerative colitis has been established. The Active ...
2009 NOV 23 ... responses, soluble drug levels and antibody formation between patients with RA receiving infliximab and adalimumab." "69 patients with RA fulfilling the 1987 American ...
2009 NOV 16 ... review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab,' are detailed in a study published in Alimentary Pharmacology & Therapeutics. ...
2009 NOV 23 ... the United States with inflammatory bowel disease (IBD) exceed 1.7 billion dollars/year. Infliximab, an antibody to tumor necrosis factor-alpha, has been extensively used to treat IBD, ...
2009 NOV 2 ... clear. The aim of this study was to assess the effects of 6-month anti-TNF treatment (infliximab) on leptin and adiponectin plasma levels in RA patients. Thirty women with RA were ...
2009 NOV 23 ... dystrophy. The biologic therapies adalimumab, alefacept, efalizumab, etanercept, and infliximab have demonstrated clinically important nail psoriasis improvements using the Nail ...
2009 NOV 16 ... States, "Practice guidelines suggest that immunomodulators (IMs) be given prior to infliximab (IFX) in patients with Crohn's disease (CD). The package insert for IFX recommends that ...
